anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Title

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 303,780
Current window 230,221-230,250
Pages 10,126
Rows per page 30
Component: Titleclear collectionreset all
18 30 60

Component

230,221-230,250 of 303,780

filter-aware
02
MAIA Biotechnology | Investor Presentation Deck | 31 slidesMAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
03
The slide outlines the status of THIO-101, 102, and 103, highlighting FDA designations and clinical trial progress.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · The Ask1 hit
04
The slide uses a custom timeline/pipeline layout to show drug development stages.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
05
MAIA Biotechnology | Investor Presentation Deck | 31 slidesMAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
06
The slide uses a three-column layout with circular callouts to emphasize demographic trends and disease prevalence.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · ProblemLoop · Why Now1 hit
07
This is a transition or thesis slide emphasizing competitive differentiation.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
08
The slide illustrates a sequential therapeutic approach: THIO treatment followed by CPI therapy.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
09
Slide highlights a strategic partnership/traction milestone.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
10
The chart demonstrates tumor volume reduction over time, highlighting the efficacy of the THIO + Atezo combination.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
11
The slide outlines a multi-part clinical trial process from Part A (Safety) through Part B (Efficacy/Dose Selection) to a planned Expansion phase.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
12
The table compares a standard of care (Cyramza), a regulatory benchmark, and the company's own drug candidate (THIO-101).MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
13
Data cut of ongoing study THIO-101 as of 13Nov2023.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
14
The slide uses a specific medical study to justify a change in clinical trial endpoint strategy.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
15
Data cut as of 13Nov2023.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
16
The chart tracks individual patient timelines, including disease progression, partial responses, and study outcomes.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
17
The slide outlines a multi-part clinical trial design (basket/umbrella) for a biotech drug candidate.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
18
The slide presents two line charts showing tumor volume reduction over time, highlighting 100% complete response (CR) and resistance to tumor rechallenge.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
19
The slide shows two line charts comparing tumor volume reduction across different treatment regimens in mouse models.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
20
The chart shows tumor volume over time, with the THIO group reaching 100% complete response (CR).MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
21
The slide presents two line charts showing tumor volume over time, illustrating the efficacy of THIO in primary treatment and rechallenge scenarios.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
22
The slide outlines a clinical trial process flow involving SCLC and NSCLC patient baskets, immune activation, and subsequent combination therapies leading to a Phase 3 expansion.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
23
MAIA Biotechnology | Investor Presentation Deck | 31 slidesMAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
24
The slide highlights both regulatory exclusivity (NCE) and a multi-layered patent strategy extending into the 2040s.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
25
Includes headshots, professional summaries, and a grid of logos representing past company affiliations.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Team1 hit
26
The slide contrasts the massive combined market of established CPIs ($42B) with the smaller market share of Libtayo ($0.5B) to frame the opportunity for partnership/growth.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Market Size1 hit
27
The slide uses market cap data to establish valuation benchmarks and cites recent M&A activity as a validation of the sector's value.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Competition1 hit
28
The slide uses a grid-based timeline layout to map specific clinical events to calendar years.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
29
MAIA Biotechnology | Investor Presentation Deck | 31 slidesMAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
30
Includes details on options, warrants, and insider ownership percentages.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
31
The slide shows a biological mechanism of action (MOA) validation using TIFs as a biomarker.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit